The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Executive Committee
      • Finance & Audit Committee
      • Governance & Nominating Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2022
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2022
    • FOCIS Symposia
  • AIRR Community
    • AIRR-C 2022 Votes
    • AIRR News
    • AIRR Community Service Prize 2022
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Research Competitions
    • Science Writing Competition
      • Science Writing Competition Winners
    • Discount codes for meeting registration
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Archives for antibody discovery

2022 Science Writing Competition winners announced!

May 15, 2022 by Janice Reichert

Congratulations to our winners!

To make science accessible, clear, concise communication is essential. The Antibody Society thus offers our student and post-doctoral fellow members a chance to grow this skill through a Science Writing Competition. Entrants submitted essays of 1200 – 1500 words on a topic related to antibody research that were evaluated by our panel of judges.

Our post-doc and student winners are:

Dr. Finn Wolfreys, University of California, San Francisco, CA, USA

Essay title: Antibody Discovery’s Diversity Problem

Alexander Brown, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Essay title: Immunity in a Deck of Cards

The winning essays can be accessed via the links above.

View all winning essays from the
Science Writing Competitions here

The  next Science Writing Competition opens in Feb. 2023.

Thanks to everyone who participated!

Filed Under: Antibody discovery, Competition, Immunology Tagged With: antibody discovery, Science Writing

Biologics Developability: Call for Papers

May 2, 2022 by The Antibody Society

Developability of biologics refers to their likelihood of success in progressing through manufacturing and clinical trials toward approval by regulatory authorities to be marketed as a drug for use in humans. A highly developable biologic should not only maintain high titer, good chemical and structural stability, resistance to various manufacturing stresses, such as low pH, shear stress, light, heat, for ease of manufacturing, but also possess target specificity, durable pharmacokinetics (PK) and low immunogenicity for assurance of safety and efficacy. Thus, developability is an umbrella concept under which manufacturability and other drug-like properties reside. Developability assessment via experimental assays or in silico analyses conducted during early-phase research can be crucial in (1) shaping lead molecule optimization strategy, (2) supporting selection of a final drug candidate molecule for progression into manufacturing, GLP toxicity studies, and other preparations for human clinical trials, and (3) reducing attrition and failure of therapeutic molecules in clinical trials. During the development stage, developability evaluation focuses more on assessment of critical quality attributes (CQAs) and quality control of product and manufacturing process-related impurities to ensure safety and efficacy.

Since the concept was introduced over a decade ago, developability is now a fast-changing field. mAbs thus aims to assemble a collection of articles reflecting the latest thinking across the industry in this area of drug research and development. As such, we invite The Antibody Society members, mAbs readers and the broader scientific community to contribute review articles focused on early stage developability assessment, and practical considerations, new technologies and strategies for CQAs assessment and control system at later stages of drug development. The reviews should narrate the state of the art and speculate on new vistas for the field.

mAbs will waive publication charges for up to 8 of the best review articles selected from pre-submission inquiries, which should consist of the title, abstract and general outline of the intended review article.

We are particularly interested in reviews in the following topics:

Early-Stage Drug Research

●        Review of the latest assays being used for assessment of developability. Include practical considerations of workflows, prioritization of assays given limited amounts of protein early on and based on known redundancies, and interpretations of assay results for decision making

●        Review of the latest in silico tools for stage appropriate risk assessment. For example, using machine learning-based data analysis and prediction for lead optimization and creating more manufacturable biologics

●        Commonalities and idiosyncrasies of manufacturability/developability assessment across non-traditional formats – ADCs vs bispecifics vs mAbs vs fragments vs Fc fusions

●        Translatability of manufacturability/developability risk assessment assays to preclinical and clinical readouts

Drug Development / CMC

●        Considerations on how product and process-related quality attributes impact PK/PD, biodistribution/retention at subcutaneous dosing sites, immunogenicity, such as host cell protein analysis and strategies used in CQA assessments

●        Practical considerations, novel strategies, and new technologies such as mass spectrometry used in generating evidence for CQAs assessment and process and product quality control

Although these topics are especially of interest, we welcome well-written reviews in related areas as well.

The deadline for the pre-submission enquiries is June 15, 2022, and the deadline for submission of the completed review articles is November 15, 2022.

Please send pre-submission inquiries to Editor-in-Chief Dr. Janice Reichert (reichert.biotechconsulting@gmail.com), and feel free to contact Assistant Editors Drs. Nathan Higginson-Scott (nathan.higginson-scott@seismictx.com), Feng Yang (yang.feng@gene.com) and Li Zhou (li.zhou@abbvie.com) if you have any questions.

Filed Under: Antibody discovery, Antibody therapeutic Tagged With: antibody discovery, antibody therapeutics

Learn about Modeling Biologic Molecules on January 27th!

January 12, 2022 by Janice Reichert

Registration is open for our next webinar, “Modeling Biologic Molecules“, to be held Thursday January 27, 2022, 11am ET / 5pm CET.

The speakers are Dr. Monica Fernández-Quintero and Prof. Klaus R. Liedl.

Modeling in Chemistry obviously depends on a strong link to reality. Even though the mathematical description of chemistry has been possible for almost 100 years, realistic modelling has only recently become available due to the recent massive increase of computing power following Moore’s law. Still, appropriate statistics, initial conditions and boundaries pose considerable challenges. Nowadays, methodological advances and progress in hardware allows the observation of biological systems for relevant time periods. Hence, dynamic processes like reorientations, folding and binding can be seen in atomistic resolution leading to completely new insights.

Describing an antibody’s binding site using only one single static structure limits the understanding and characterization of the antibody’s function and properties, whereas various biophysical properties are governed by its dynamics, e.g., antibody-antigen binding. This limitation is even more pronounced when no experimentally determined structure is available or the crystal structure is distorted by packing effects, which can result in misleading antibody paratope structures. To improve antibody structure prediction and to take the strongly correlated CDR loop and interface movements into account, antibody paratopes should be described as interconverting states in solution with varying probabilities. These kinetically characterized paratope ensembles with their respective state probabilities allow the identification of the dominant conformation in solution, which frequently has been shown to coincide with the binding competent conformation. Therefore, the definition of kinetically and functionally relevant states, so-called paratope states, can be successfully used to improve the accuracy and enhance the predictivity of antibody-antigen docking.

Register for this webinar here!

Filed Under: Antibody discovery, Antibody therapeutic, Bioinformatics Tagged With: antibody discovery, antibody therapeutics, bioinformatics

Career Shorts Ep 2 – Dr Nimish Gera

October 18, 2021 by Raquel Ferro

After the launch of our new Career Shorts series last week, we are proud to release our second episode with Dr Nimish Gera, Head of Biologics at Mythic Therapeutics! Check out our new episode via our new YouTube channel using the link below.

Career Shorts Ep 2: https://youtu.be/kOpuBxNdS5A

 

Our previous episode (Ep 1 with Dr Li Zhou): https://youtu.be/Y9xtGRLQaSM
Career shorts webpage: https://www.antibodysociety.org/career-shorts/

About Career shorts:

In this series, we talk to scientists and individuals working within the world of antibodies about the experiences that have shaped their careers and have got them to where they are today. Our goal by sharing their experiences and advice is to empower the next generation of scientists and leaders working in this field and beyond to make confident and empowered decisions.

Filed Under: Antibody discovery, Careers Tagged With: antibody discovery, antibody engineering, Careers

Career Shorts

October 11, 2021 by Raquel Ferro

The Antibody Society is proud to present Career Shorts!

In this series, we talk to scientists and individuals working within the world of antibodies about the experiences that have shaped their careers and have got them to where they are today. Our goal by sharing their experiences and advice is to empower the next generation of scientists and leaders working in this field and beyond to make confident and empowered decisions.

We kick off our first episode by talking to Dr Li Zhou, principle scientist at AbbVie. This episode and more will be made accessible via our new YouTube channel. Check out the full interview in the link below and stay tuned for more exciting releases!

 

Career Shorts Ep 1: Dr Li Zhou: https://youtu.be/Y9xtGRLQaSM
Career shorts webpage: https://www.antibodysociety.org/career-shorts/

Filed Under: Antibody discovery, Career Shorts, Uncategorized Tagged With: antibody discovery, antibody engineering, career shorts, Careers

Next Page »

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • 2022 Science Writing Competition winners announced! May 15, 2022
  • Our Antibody Research Competition is open! May 4, 2022
  • Biologics Developability: Call for Papers May 2, 2022

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals